Ost-müük DiaMedica Therapeutics Inc. - DMAC CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.1100 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 1.5458 |
| Avatud* | 1.545 |
| Aastane muutus* | -44.42% |
| Päeva ulatus* | 1.545 - 1.575 |
| 52 nädala ulatus | 1.12-3.06 |
| Keskmine maht (10 päeva) | 26.19K |
| Keskmine maht (3 kuud) | 827.55K |
| Turukapitalisatsioon | 45.48M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 26.44M |
| Tulu | N/A |
| EPS | -0.50 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.76 |
| Järgmine tuluaruande kuupäev | Mar 28, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 1.5458 | -0.0479 | -3.01% | 1.5937 | 1.6633 | 1.5454 |
| Mar 21, 2023 | 1.6729 | -0.0391 | -2.28% | 1.7120 | 1.7122 | 1.5843 |
| Mar 20, 2023 | 1.6925 | -0.0382 | -2.21% | 1.7307 | 1.7314 | 1.6529 |
| Mar 17, 2023 | 1.7316 | -0.0188 | -1.07% | 1.7504 | 1.7505 | 1.7010 |
| Mar 16, 2023 | 1.8296 | 0.0891 | 5.12% | 1.7405 | 1.8394 | 1.7405 |
| Mar 15, 2023 | 1.6923 | -0.0383 | -2.21% | 1.7306 | 1.7416 | 1.6820 |
| Mar 14, 2023 | 1.7805 | 0.0878 | 5.19% | 1.6927 | 1.8297 | 1.6422 |
| Mar 13, 2023 | 1.6922 | 0.1276 | 8.16% | 1.5646 | 1.7221 | 1.5646 |
| Mar 10, 2023 | 1.6531 | -0.0182 | -1.09% | 1.6713 | 1.7019 | 1.5645 |
| Mar 9, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7707 | 1.6421 |
| Mar 8, 2023 | 1.7709 | 0.0994 | 5.95% | 1.6715 | 1.7906 | 1.6715 |
| Mar 7, 2023 | 1.7219 | 0.0798 | 4.86% | 1.6421 | 1.7221 | 1.6421 |
| Mar 6, 2023 | 1.7020 | -0.0188 | -1.09% | 1.7208 | 1.7612 | 1.6723 |
| Mar 3, 2023 | 1.7316 | 0.0790 | 4.78% | 1.6526 | 1.7514 | 1.6526 |
| Mar 2, 2023 | 1.7414 | 0.0300 | 1.75% | 1.7114 | 1.7612 | 1.7114 |
| Mar 1, 2023 | 1.7315 | -0.0294 | -1.67% | 1.7609 | 1.7609 | 1.6428 |
| Feb 28, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7416 | 1.6421 |
| Feb 27, 2023 | 1.6535 | 0.0099 | 0.60% | 1.6436 | 1.7024 | 1.5842 |
| Feb 24, 2023 | 1.6729 | 0.0297 | 1.81% | 1.6432 | 1.6828 | 1.6333 |
| Feb 23, 2023 | 1.6925 | -0.0089 | -0.52% | 1.7014 | 1.7604 | 1.6822 |
DiaMedica Therapeutics Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0.5 | 0 |
| Kogu tegevuskulu | 13.646 | 12.699 | 11.593 | 7.261 | 4.519 |
| Müük/Üldine/admin kulud, kokku | 4.881 | 4.389 | 3.693 | 2.739 | 1.313 |
| Uuringud ja arendus | 8.765 | 8.31 | 7.9 | 4.522 | 3.206 |
| Depreciation / Amortization | |||||
| Tulud majandustegevusest | -13.646 | -12.699 | -11.593 | -6.761 | -4.519 |
| Intressitulud (kulu), muud tulud, neto | 0 | -0.039 | 0.009 | ||
| Muud, neto | 0.082 | 0.434 | 0.975 | 1.146 | 0.25 |
| Netotulu enne makse | -13.564 | -12.265 | -10.618 | -5.654 | -4.26 |
| Netotulu pärast makse | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Netotulu enne erikulusid | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Netotulu | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Arvestatav tulu, v a erikulud | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Arvestatav tulu, koos erikuludega | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Jaotamisele kuuluv netotulu | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Keskmine jaotamisele kuuluv aktsia kohta | 20.7734 | 15.6803 | 11.9877 | 7.74352 | 5.93579 |
| Jaotatav EPS, v a erakorralised kulud | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Jaotamisele kuuluv normaal-EPS | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
| Tulu | 0 | 0.5 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 3.536 | 3.246 | 3.416 | 3.365 | 3.619 |
| Müük/Üldine/admin kulud, kokku | 1.562 | 1.375 | 1.084 | 1.209 | 1.213 |
| Uuringud ja arendus | 1.974 | 1.871 | 2.332 | 2.156 | 2.406 |
| Tulud majandustegevusest | -3.536 | -3.246 | -3.416 | -3.365 | -3.619 |
| Muud, neto | 0.035 | 0.007 | -0.027 | 0.098 | 0.004 |
| Netotulu enne makse | -3.501 | -3.239 | -3.443 | -3.267 | -3.615 |
| Netotulu pärast makse | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Netotulu enne erikulusid | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Netotulu | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Arvestatav tulu, v a erikulud | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Arvestatav tulu, koos erikuludega | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Jaotamisele kuuluv netotulu | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
| Keskmine jaotamisele kuuluv aktsia kohta | 26.4431 | 26.5021 | 19.0357 | 18.7862 | 18.7667 |
| Jaotatav EPS, v a erakorralised kulud | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 45.439 | 27.921 | 8.836 | 17.972 | 1.494 |
| Raha ja lühiajalised investeeringud | 45.112 | 27.507 | 7.878 | 16.823 | 1.353 |
| Cash | 4.707 | 7.409 | 3.883 | 16.823 | 1.353 |
| Laekumata arved, neto | 0.13 | 0.34 | 0.823 | 0.78 | 0.08 |
| Prepaid Expenses | 0.084 | 0.064 | 0.047 | 0.369 | 0.061 |
| Total Assets | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Property/Plant/Equipment, Total - Net | 0.112 | 0.174 | 0.217 | 0.096 | 0.037 |
| Property/Plant/Equipment, Total - Gross | 0.179 | 0.231 | 0.26 | ||
| Accumulated Depreciation, Total | -0.067 | -0.057 | -0.043 | ||
| Total Current Liabilities | 1.524 | 2.028 | 1.318 | 1.296 | 1.003 |
| Accounts Payable | 0.509 | 1.099 | 0.182 | ||
| Accrued Expenses | 1.011 | 0.923 | 1.13 | ||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.084 | |||
| Total Liabilities | 1.527 | 2.081 | 1.436 | 1.314 | 1.003 |
| Total Long Term Debt | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Other Liabilities, Total | 0 | 0.046 | 0.105 | ||
| Total Equity | 44.024 | 26.014 | 7.617 | 17.025 | 0.799 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.576 | 94.925 | 64.232 | 62.993 | 41.033 |
| Retained Earnings (Accumulated Deficit) | -82.501 | -68.909 | -56.617 | -45.968 | -40.234 |
| Other Equity, Total | -0.051 | -0.002 | 0.002 | ||
| Total Liabilities & Shareholders’ Equity | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
| Total Common Shares Outstanding | 26.4431 | 18.7462 | 12.0069 | 11.9569 | 6.37066 |
| Accounts Receivable - Trade, Net | 0.13 | 0.78 | 0.08 | ||
| Other Long Term Assets, Total | 0 | 0.271 | 0.271 | ||
| Payable/Accrued | 1.291 | 0.919 | |||
| Current Port. of LT Debt/Capital Leases | 0.004 | 0.006 | 0.006 | 0.005 | 0 |
| Capital Lease Obligations | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
| Lühiajalised investeeringud | 40.405 | 20.098 | 3.995 | ||
| Other Current Assets, Total | 0.113 | 0.01 | 0.088 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 42.111 | 45.439 | 48.537 | 21.629 | 24.195 |
| Raha ja lühiajalised investeeringud | 41.047 | 45.112 | 48.097 | 21.295 | 23.401 |
| Cash | 3.032 | 4.707 | 16.219 | 2.228 | 3.329 |
| Lühiajalised investeeringud | 38.015 | 40.405 | 31.878 | 19.067 | 20.072 |
| Laekumata arved, neto | 0.168 | 0.13 | 0.104 | 0.016 | 0.337 |
| Prepaid Expenses | 0.793 | 0.084 | 0.336 | 0.318 | 0.457 |
| Total Assets | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Property/Plant/Equipment, Total - Net | 0.1 | 0.112 | 0.127 | 0.145 | 0.161 |
| Property/Plant/Equipment, Total - Gross | 0.162 | 0.179 | 0.187 | 0.199 | 0.209 |
| Accumulated Depreciation, Total | -0.062 | -0.067 | -0.06 | -0.054 | -0.048 |
| Total Current Liabilities | 1.434 | 1.524 | 1.624 | 1.44 | 1.178 |
| Accounts Payable | 0.433 | 0.509 | 0.699 | 0.239 | 0.689 |
| Accrued Expenses | 0.995 | 1.011 | 0.921 | 1.196 | 0.483 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.006 | 0.004 | 0.004 | 0.005 | 0.006 |
| Total Liabilities | 1.443 | 1.527 | 1.628 | 1.456 | 1.211 |
| Total Long Term Debt | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Capital Lease Obligations | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
| Other Liabilities, Total | 0 | 0 | 0.011 | 0.028 | |
| Total Equity | 40.768 | 44.024 | 47.036 | 20.318 | 23.145 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 126.884 | 126.576 | 126.296 | 96.126 | 95.68 |
| Retained Earnings (Accumulated Deficit) | -86.009 | -82.501 | -79.255 | -75.805 | -72.531 |
| Other Equity, Total | -0.107 | -0.051 | -0.005 | -0.003 | -0.004 |
| Total Liabilities & Shareholders’ Equity | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
| Total Common Shares Outstanding | 26.4431 | 26.4431 | 26.4392 | 18.7862 | 18.7862 |
| Accounts Receivable - Trade, Net | 0.166 | 0.13 | |||
| Other Current Assets, Total | 0.103 | 0.113 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
| Raha majandustegevusest | -12.252 | -9.185 | -9.102 | -5.696 | -3.9 |
| Raha majandustegevusest | 0.024 | 0.021 | 0.021 | 0.015 | 0.004 |
| Mittelikviidsed varad | 1.777 | 1.891 | 1.139 | 0.659 | 0.4 |
| Makstud intressid | 0.002 | 0.002 | |||
| Muutused tööjõus | -0.461 | 1.195 | 0.387 | -0.636 | -0.044 |
| Tulu investeeringutelt | -20.537 | -16.134 | -3.908 | -0.05 | -0.022 |
| Kapitalikulutused | -0.022 | -0.047 | -0.002 | -0.05 | -0.022 |
| Rahavood investeeringutelt | 30.087 | 28.845 | 0.07 | 21.216 | 3.539 |
| Aktsiate emiteerimine (tagasiost), neto | 30.093 | 28.85 | 0.075 | 21.216 | 3.539 |
| Muutused valuutakursside kõikumisest | |||||
| Rahaline kogumuutus | -2.702 | 3.526 | -12.94 | 15.47 | -0.383 |
| Cash Taxes Paid | 0.028 | 0.036 | 0.026 | ||
| Muud rahavood investeeringutelt, kokku | -20.515 | -16.087 | -3.906 | ||
| Laenu väljastamine (kustutamine), neto | -0.006 | -0.005 | -0.005 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.508 | -13.592 | -10.346 | -6.896 | -3.622 |
| Cash From Operating Activities | -3.888 | -12.252 | -9.448 | -6.402 | -4.313 |
| Cash From Operating Activities | 0.006 | 0.024 | 0.018 | 0.012 | 0.006 |
| Non-Cash Items | 0.443 | 1.777 | 1.354 | 1.023 | 0.551 |
| Changes in Working Capital | -0.829 | -0.461 | -0.474 | -0.541 | -1.248 |
| Cash From Investing Activities | 2.214 | -20.537 | -11.848 | 0.98 | -0.009 |
| Capital Expenditures | 0 | -0.022 | -0.015 | -0.013 | -0.009 |
| Other Investing Cash Flow Items, Total | 2.214 | -20.515 | -11.833 | 0.993 | 0 |
| Cash From Financing Activities | -0.001 | 30.087 | 30.106 | 0.241 | 0.242 |
| Issuance (Retirement) of Stock, Net | 0 | 30.093 | 30.111 | 0.244 | 0.244 |
| Issuance (Retirement) of Debt, Net | -0.001 | -0.006 | -0.005 | -0.003 | -0.002 |
| Net Change in Cash | -1.675 | -2.702 | 8.81 | -5.181 | -4.08 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
| Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
| Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
| Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.961 | 782989 | 349 | 2022-12-31 | LOW |
| Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
| Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
| Jacob Asset Management of New York, LLC | Investment Advisor | 0.8839 | 233730 | -4770 | 2022-12-31 | LOW |
| Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6991 | 184870 | -349 | 2022-12-31 | LOW |
| Lynch (Timothy Patrick) | Individual Investor | 0.3792 | 100259 | -100000 | 2022-12-31 | LOW |
| Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2723 | 72012 | 2814 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2496 | 65997 | 1067 | 2022-12-31 | LOW |
| Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | |
| Morgan Stanley & Co. LLC | Research Firm | 0.1672 | 44201 | 2194 | 2022-12-31 | MED |
| Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.1483 | 39216 | 4304 | 2022-12-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
DiaMedica Therapeutics Inc. Company profile
Ettevõttest DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte keskendub neuroloogiliste ja neeruhaiguste, näiteks ägeda isheemilise insuldi (AIS) ja kroonilise neeruhaiguse (CKD) ravimeetodite väljatöötamisele. Ettevõtte juhtiv toode DM199 imiteerib looduslikult esinevate inimese KLK1 valkude käitumist, et säilitada ja taastada insuldi kahjustatud kudede vereringet ning parandada üldist neerufunktsiooni. KLK1 on seriinproteaas ehk valk, mida toodetakse peamiselt neerudes, kõhunäärmes ja süljenäärmetes. DM199-ravil on potentsiaali parandada vereringet ja kriitiliste süsteemide üldist funktsiooni, samuti vähendada põletikku ja oksüdatiivset stressi. Ettevõttel on ka teisi tooteprogramme IgA nefropaatia ja CKDga afroameeriklaste raviks.
| Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com